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KEY MESSAGES: 
 Currently there are no definitive estimates of either the prevalence of rectal chlamydia, of concurrent 
rectal and urogenital chlamydia infection or of the relationship between anal intercourse and rectal 
chlamydia infection.  
 This systematic review found high rates of concurrent rectal infection in women with urogenital 
infection and no evidence that a history of anal intercourse is a reliable indicator for rectal chlamydia 
infection. 
 Using reported anal intercourse as an indicator for rectal testing is likely to lead to missed diagnoses of 
rectal infections. 
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ABSTRACT:  
Objectives: 
Chlamydia trachomatis is the most commonly diagnosed bacterial sexually transmitted infection. 
Lack of prevalence and risk factor data for rectal chlamydia  in women have testing and treatment 
implications, as azithromycin (a first-line urogenital chlamydia treatment) may be less-effective for 
rectal chlamydia. We conducted a systematic review of studies in women in high-income countries 
to estimate rectal chlamydia prevalence, concurrency with urogenital chlamydia and associations 
with reported anal intercourse (AI).  
Design:  
Systematic review and four meta-analyses conducted using random-effects modelling.  
Data sources: 
Medline, Embase, CINAHL, PsychINFO and the Cochrane Database were searched for articles 
published between January 1997 and October 2017.  
Eligibility criteria: 
Studies reporting rectal chlamydia positivity in heterosexual ≥15 year-old women in high-income 
countries were included. Studies must have used nucleic acid amplification tests and reported both 
total number of women tested for rectal chlamydia and number of rectal chlamydia infections 
detected. Conference abstracts, case reports and studies with self-reported diagnoses were 
excluded.  Data extracted included setting, rectal and urogenital chlamydia testing results, AI history 
and demographics.  
Results:  
Fourteen eligible studies were identified, all among diverse populations attending sexual health 
services. Among routine clinic-attending women: summary rectal chlamydia positivity was 6·0% 
(95%CI 3·2 to 8·9%); summary concurrent rectal chlamydia infection was  68·1% in those who tested 
positive for urogenital chlamydia (95%CI 56·6 to 79·6%); of those who tested negative for urogenital 
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chlamydia 2·2% (95%CI 0 to 5·2%) were positive for rectal chlamydia. Reported AI was not associated 
with rectal chlamydia (summary RR 0·90; 95%CI 0·75 to 1·10).  
Conclusions: 
High levels of rectal chlamydia infection have been shown in women with urogenital chlamydia 
infection. The absence of association between reported AI and rectal chlamydia suggests AI is not an 
adequate indicator for rectal testing. Further work is needed to determine policy and practice for 
routine rectal testing in women. 
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Detection of Chlamydia trachomatis in rectal specimens in women and its association with anal 
intercourse: a systematic review and meta-analysis 
 
INTRODUCTION: 
Chlamydia trachomatis (CT) is the most commonly diagnosed bacterial sexually transmitted infection 
(STI) in high- and middle-income countries, primarily infecting urogenital and rectal mucosa1,2. 
Failure to identify and treat urogenital CT can result in serious sequelae such as pelvic inflammatory 
disease, tubal scarring, ectopic pregnancy and infertility1,3. Rectal CT infection is largely 
asymptomatic, and is associated with increased risk of HIV transmission and acquisition4,5.  High 
concurrency of rectal and urogenital CT in men and women has been observed in some studies, 
suggesting significant numbers of rectal CT cases may be missed by genital testing alone6-9.  
The clinical significance of rectal CT infection in women is unclear, as the risks of long-term sequelae 
following a rectal infection in women are unknown9. A positive nucleic acid amplification test (NAAT) 
result may not represent viable organisms emerging from rectal mucosal intracellular CT infection (a 
true infection), and instead be indicative of contamination of either DNA or CT organisms from the 
urogenital tract to the rectum. However van Liere et al., 2016 have shown comparable bacterial 
loads in rectal and in urogenital swabs, supporting the premise that detection of CT in the rectum 
can indicate a biological infection rather than contamination in women with and without a history of 
anal intercourse (AI)10.  Henceforth, we assume that a positive test means an established CT 
infection. Undiagnosed, untreated and under-treated rectal CT infections constitute a potential 
reservoir of CT and given the possibility of auto-inoculation of CT from the rectum to the urogenital 
tract11,12 may impede effective treatment and transmission prevention. 
A recent meta-analysis and other work suggest that azithromycin, a first line treatment for 
uncomplicated urogenital CT, may only be around 80% effective when treating rectal CT2,13,14.  
Consequently, the World Health Organization (WHO) and the British Association for Sexual Health 
and HIV (BASHH) recommend doxycycline as the preferred treatment for rectal CT with the former 
specifically recommending doxycycline if AI is reported2,15. In England, 11% of women aged 16-74 
years reported AI in the previous year. There is inconsistent evidence for history of AI as a rectal CT 
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indicator9,16-20. However, WHO guidelines currently recommend that a history of AI guide the 
decision to test for rectal CT15. 
Many countries have policies for opportunistic urogenital CT testing and treatment such as the 
National Chlamydia Screening Programme (NCSP) in England, which tests approximately 1·7 million 
people aged 15-24 and identifies around 140,000 infections annually1,21,22. Having unidentified 
reservoirs of rectal CT in women tested only for urogenital CT risks reduced effectiveness and cost-
effectiveness of these CT control programmes.  
We conducted a systematic review and meta-analyses of studies measuring rectal CT positivity in 
women in order to estimate rectal CT prevalence, concurrency with urogenital CT and the  
association between rectal CT and reported history of AI.  
METHODS: 
Search strategy and selection criteria: 
We searched electronic bibliographic databases, Medline, Embase, CINAHL, PsychINFO and the 
Cochrane Database from 1st January 1997 to 2nd September 2015 using free text terms and medical 
subject headings combining all terms for Chlamydia trachomatis, prevalence, positivity, 
epidemiology, diagnosis, and rectal, anal or anogenital (supplementary material 1). Additionally, we 
hand-searched references of included papers for other relevant papers.  Conference abstracts were 
not included. Using the same method, we undertook an additional Medline search between 1st 
January 2015 and 17th October 2017 to ensure that all relevant recently published articles were 
included in the review.  
We included cross-sectional studies of general and clinic-attending populations, which could be 
nested in cohort studies or randomised controlled trials, involving heterosexual women aged ≥15 
years who were tested for rectal CT. Studies must have used NAATs and reported both total number 
of women tested for rectal CT and number of rectal diagnoses. Case reports and studies with self-
reported diagnoses were excluded. Studies were limited to those conducted in high-income 
countries (defined by the Organization for Economic Cooperation and Development [OECD]), as 
these countries were most likely to have similar healthcare provision and CT epidemiology.  
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Abstracts and full-texts were independently reviewed by two reviewers for eligibility. Disagreements 
were resolved with a third reviewer. Where necessary, study authors were contacted for more 
information.  
Data were extracted independently by two reviewers, compared and discrepancies resolved with a 
third reviewer. Data extracted included information on study design, inclusion criteria, outcome of 
interest and funding information (supplementary material 2).  Urogenital and rectal infections were 
defined as a positive NAAT from a site specific swab which was not part of a pooled sample.  We 
assume that a positive rectal swab for CT in a woman represents an active and established rectal CT 
infection. Data were extracted from papers which reported any history of AI by rectal CT test result 
(AI not specifically defined).  
Risk-of-bias was assessed by two independent reviewers using a published tool adapted from Hoy et 
al., 201223  to determine whether included studies would present a biased estimate of population 
prevalence. The tool assesses risk of bias using  structured questions to appraise internal and 
external validity of each study. The reviewers collated their evaluations of each paper and agreed on 
an overall risk for each paper.  
Data analysis: 
The positivity of rectal infection among participants in each study was calculated, defined as 
percentage of women with a rectal CT infection among all women in the study tested for rectal CT.   
Four meta-analyses were conducted, using random effects models to calculate:  
1) Summary estimates of rectal CT positivity across all studies stratified by tested population or 
clinical subgroup: a) routine clinic-attenders (not defined as high-risk as below), N=3; b) women of 
high risk (sexual contacts of gonorrhoea-positive individuals,  had symptoms, victims of sexual 
assault, had sexual contact with someone diagnosed with CT, or were being followed-up for CT and 
adult film industry performers) N=4; c) women who were tested only because they reported a 
history of AI, N=5; d) women who were tested for rectal CT because they were positive for 
urogenital CT, N=1; and e) women who were all HIV positive, N=1.  
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2) Summary estimates of proportion of women with rectal CT among women who were positive for 
urogenital CT in all appropriate studies and among studies reporting routine clinic-attenders. These 
women represent a population who may have an undiagnosed rectal CT infection but have 
treatment directed towards their urogenital CT infection which may not be the recommended first 
line treatment for rectal CT (doxycycline), hereafter we refer to this as ‘less-effectively treated’. 
3) Summary estimates of proportion of women with rectal CT among those negative for urogenital 
CT in all appropriate studies and among studies reporting routine clinic-attenders, as a measure of 
potential undiagnosed rectal infection among those tested.  
4) Summary risk ratio (RR) for being rectal CT positive in women who had reported a history of AI in 
order to determine the utility of reporting AI as an indicator for rectal testing.  
Where heterogeneity was high (more than 75%) summary estimates are not reported (with 
exception of routine clinic-attending women), only a range and median average of the results are 
reported. 
Additional data were extracted on specimen type and site tested (supplementary material 3), but 
were not analysed to determine association with positivity. 
All meta-analyses were undertaken using STATA-13 (Stata Statistical Software: StataCorp LP, TX), 
using the metaprop (analyses  1-3)and metan (analysis 4) commands. We tested for variation in 
estimated proportions (analyses 1-3) or risk ratios (analysis 4) attributable to heterogeneity using 
the I2 statistic and estimated between-study variance using the Τ2 statistic. A fixed continuity 
correction of 0.5 was added in cases where a study had a zero result, to ensure all studies could be 
included, where appropriate, in analyses24,25. 
RESULTS: 
From 681 unique references identified from the database search 14 studies were included in the 
meta-analyses (figure 1): 12 cross-sectional studies and two observational cohort studies (table 1).  
Of these 14 studies, five only tested women for rectal CT if they had reported a history of AI8,26-29; 
one conducted only among HIV positive women30; one conducted only among urogenital CT positive 
participants9; one conducted among adult film industry performers31; three studies tested clinic-
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attendees considered to be high risk (defined as women who were sexual contacts of gonorrhoea-
positive individuals, had symptoms, were victims of sexual assault, had sexual contact with someone 
diagnosed with CT, or were being followed-up)7,32,33; and three studies included all eligible routine 
clinic attendees16,17,34. All studies identified were of women attending sexual health settings, no 
studies conducted among a general population sample were identified.   
Figure 1: Flow chart depicting the selection of studies for inclusion in the review process 
 
Using the adapted risk-of-bias tool23, all studies were considered to have an overall high risk-of-bias 
in measuring population prevalence given that they each sampled from specific groups which were 
unlikely to represent the general population of sexually active women in their respective countries. 
Some answers varied by reviewer but the overall risk was found to be the same (supplementary 
material 4). 
No study provided an estimated population prevalence of rectal CT.  Among all 14 studies, rectal CT 
positivity ranged from 1·7-77·3% with a median of 8·9% (table 1).  Due to the high heterogeneity 
between studies (I2=97·2%, Τ2=0·01) a summary estimate was not calculated for all studies.  
For the studies reporting routine clinic-attending women, although high heterogeneity was seen 
across the three studies the subgroup summary estimate for rectal CT positivity was 6·0% (95%CI 
3·2-8·9%, I2=84·6%, Τ2=0·01). For the studies where all women were reporting a  history of AI the 
summary estimate for rectal CT positivity was 25·9% (95%CI 8·5- 43.3%, I2=65·2%, Τ2=0·00 ) (figure 
2). 
 
 
Figure 2: Individual study and  study subgroup summary estimates of rectal chlamydia positivity in women stratified by 
clinical subgroup/population type (N=14) 
The diamonds represent the summary proportions and confidence intervals by subgroup; CI = Confidence intervals; 
CT=Chlamydia trachomatis. 
*Women of high risk category includes sexual contacts of gonorrhoea-positive individuals, had symptoms, were victims of 
sexual assault, had sexual contact with someone diagnosed with CT, or were being followed-up, as well as adult film 
industry performers (potentially high risk due the number of sexual events, however safe-sex and sexual health testing 
practice is unknown). 
 
Ten studies reported testing for urogenital CT and rectal CT7-9,16,17,27,31-34.  Among these studies where 
all women tested for rectal CT and urogenital CT, a concurrent infection was found in 3·6-81·5% 
(median, 11·8%) (table 2). Among studies  where women were positive for CT regardless of site of 
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infection,  concurrent urogenital CT and rectal CT was found in 40·9-100% (median, 78·5%; 
calculated using columns from table 2 A/(A+B+C)). In studies, in which women  were positive for 
rectal CT, a concurrent urogenital CT infection was found in 62·9-100% (median, 94·3%; A/(A+C)) 
(table 2).  
High heterogeneity was found between the ten studies (I2=80·9%, Τ2=0·01). The proportion of 
women having a rectal CT infection among those positive for urogenital CT ranged between 45.0-
100%. This range represents a worst case scenario of women at risk of being less-effectively treated, 
(i.e. women with undiagnosed rectal CT who do not receive recommended first line treatment for 
rectal CT) (supplementary material 5a). The summary estimate of rectal CT infection among those 
positive for urogenital CT across studies reporting only routine clinic-attenders was 68.1% (95%CI 
56·6-79·6%, I2=70.9%, Τ2=0·03). 
A summary estimate among those who tested negative for urogenital CT was not provided due to 
the high heterogeneity (I2=91·0%, Τ2<0.0001). The proportion of women with a rectal CT infection 
among women who tested negative for urogenital CT ranged from 0.0-11.5%. This range represents 
the potential proportion of women with a CT infection who may have been undiagnosed and 
untreated (supplementary material 5b).  Although a high heterogeneity was found, the summary 
estimate for studies reporting only routine clinic-attenders, was 2·2% (95%CI 0-5·2%, I2=97.3%, 
Τ2=0·001). 
Eleven studies had information on history of AI7-9,16,17,26-29,32-34. The definition of “history of AI” was 
inconsistent across the studies or not specified. Among all women who were tested for rectal CT, 
2·0-30·4% (median, 9·1%; F/J) had a positive test and reported AI (table 2). Among all women who 
had a positive rectal CT infection, between 13·5-100% (median, 51·6%; F/(F+H)) reported AI. 
However these included five studies that only tested women who reported AI; without these five 
studies8,26-29, the range is 13·5-50·0% (median 29·1%) (table 2).   
The calculated summary RR for a history of AI as a risk factor for rectal CT was 0·90 (95%CI 0·74-1·10, 
I2=5·6%, Τ2=0·004) (supplementary material 6).  
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Table 1: Study characteristics and rectal chlamydia positivity of all included studies (N=14). 
*One woman was excluded from the number tested because she was less than 15 years old;  she tested negative for rectal chlamydia. Reported number of women tested is 3055.  **No maximum age provided 
Study 
Country of 
study 
Study design Study population tested 
Age range 
(years) 
Data collection 
period 
Number of women 
tested 
Rectal chlamydia 
positivity in women (n) 
Bachmann et al., 2010 7 United States Cross-sectional  
Sexual Health clinic attending 
population 
16-44 Jul 2003–Feb 2007 99 34·3% (34) 
Bazan et al., 2015 8 United States Observational cohort 
Sexual Health clinic attending 
population 
16-66 Aug 2012–Jun 2013 341 13·5% (46) 
Cosentino et al., 2012 26 United States Cross-sectional  
Sexual Health clinic attending 
population 
18-64 May 2009–Mar 2010 272 7·7% (21) 
Ding and Challenor, 2013 9 United Kingdom Cross-sectional  
Urogenital chlamydia positive, 
Sexual Health clinic attending 
population 
16-53 Apr 2012–Jun 2013 97 77·3% (75) 
Garner et al., 201529 United Kingdom Cross-sectional 
Sexual Health clinic attending 
population 
16-66 Mar 2010– May 2010 91 6.6% (6) 
Gratrix et al., 2015 17 Canada Cross-sectional  
Sexual Health clinic attending 
population 
14-70* Jul 2012–Dec2012 3054* 4·3% (132) 
Hunte et al., 2010 27 United States Cross-sectional  
Sexual Health clinic attending 
population 
17-46 May 2007–Aug 2008 97 17·5% (17) 
Mayer et al., 2012 30 United States Observational cohort  
HIV positive population attending a 
sexual health clinic 
21-69 Mar 2004–Jun 2006 119 1·7% (2) 
Musil et al., 201633 Australia Cross-sectional 
Sexual Health clinic attending 
population 
15-54 Nov 2013–Jun 2014 56 57.1% (32) 
Ostergaard et al., 1997 34 Denmark Cross-sectional  
Sexual Health clinic attending 
population 
18-53 Dec 1995–Jul 1996 196 5·6% (11) 
Rodriguez-Hart et al., 2012 31 United States Cross-sectional  Adult film industry performers 18-42 May 2010–Sep 2010 112 3·6% (4) 
Sethupathi et al., 2010 32 United Kingdom Cross-sectional  
Sexual Health clinic attending 
population 
15-62 Sep2006–Aug 2008 159 12·6% (20) 
van Liere et al., 2014 16 Netherlands Cross-sectional  
Sexual Health clinic attending 
population 
18-99** May 2012–Jul 2013 654 8·4% (55) 
van Rooijen et al., 201528 Netherlands Cross-sectional 
Sexual Health clinic attending 
population 
15-99** Jan 2011–Jul2012  1656 9.3% (154) 
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Table 2: Data extracted from studies reporting women tested for urogenital chlamydia and/or studies reporting a history of anal intercourse 
rectal CT= Rectal chlamydia urogenital CT= Urogenital chlamydia; -ve=negative, +ve=positive, AI=anal intercourse 
A/E= Concurrent infection among women tested for rectal CT; A/(A+B+C)= Concurrent infection among all women positive for CT regardless of site; A/(A+C)=Concurrent infection among women positive for rectal 
CT; F/J=Women positive for rectal CT and reported AI among  all women tested for rectal CT; F/(F+H)= Women who reported AI among all women positive for rectal CT 
Study 
Data for studies reporting urogenital CT testing Data for studies reporting a history of AI 
Additional information 
Number of women (%): Number of women (%): 
Rectal CT+ve 
and 
urogenital 
CT+ve 
Rectal CT-ve 
and 
urogenital 
CT+ve 
Rectal CT+ve 
and 
urogenital 
CT-ve 
Rectal CT-ve 
and 
urogenital 
CT-ve 
Total Rectal CT+ve 
and 
AI reported 
Rectal CT-ve 
and 
AI reported 
Rectal CT+ve 
and 
No AI 
reported 
Rectal CT-ve 
and 
No AI 
reported 
Total 
 A B C D E F G H I J  
Bachmann et al., 2010 7 20 (23·8) 3 (3·6) 7 (8·3) 54 (64·3) 84· 9 (9·0) 30 (30·0) 25 (25·0) 36 (36·0) 100· High risk settings (STD clinic and three HIV 
clinics) and women tested  if were at high risk 
or had a history of AI. 
Bazan et al., 2015 8 38 (11·4) 5 (1·5) 6 (1·8) 285 (85·3) 334 46 (13·5) 295 (86·5) n/a n/a 341 All women reported a history of AI. 
Cosentino et al., 2012 26      21 (7·7) 251 (92·3) n/a n/a 272 No data reported for urogenital CT infections. 
All women reported a history of AI. 
Ding and Challenor, 20139 97 (81·5) 22 (18·5) n/a n/a 119 20 (20·6) 5 (5·2) 55 (56·7) 17 (17·5) 97 All women were positive for a urogenital CT 
infection. 
Garner et al., 201529      6 (6.6) 85 (93.4) n/a n/a 91 All women reported a history of AI. 
Gratrix et al., 2015 17 224 (7·3) 76 (2·5) 132 (4·3) 2622 (85·9) 3054 48 (13·0) 13 (3·5) 308 (83·5)   
 
Number of women who had a negative rectal 
CT test and did not report a history of AI is 
unknown from the data reported. 
Hunte et al., 2010 27 16 (16·5) 0 1 (1·0) 80 (82·5) 97 17 (17·5) 80 (82·5) n/a n/a 97 All women reported a history of AI. 
Mayer et al., 2012 30           No data on urogenital CT collected. No data on 
history of AI collected. All women were HIV 
positive. 
Musil et al., 201633 31 (55.4) 7 (12.5) 1(1.8) 17 (30.4) 56 17 (30.4) 17 (30.4) 15 (26.8) 7 (12.5) 56 Women at high risk of infection (had 
symptoms, follow up, sexual contactwith a 
positive case) 
Ostergaard et al., 1997 34 9 (4·6) 11 (5·6) 2 (1·0) 174 (88·8) 196 4 (2·0) 82 (41·8) 7 (3·6) 103 (52·6) 196  
Rodriguez-Hart et al., 
2012 31 
4 (3·6) 0 0 108 (96·4) 112      Of all women tested, four were positive for 
concurrent infections only. No data on history 
of AI reported. 
 
Sethupathi et al., 2010 32 19 (12·2) 3 (1·9) 1 (0·6) 133 (85·3) 156 10 (6·3) 72 (45·0) 10 (6·3) 68 (42·5) 160 Women considered to be at high risk were 
tested for rectal CT (women who had contacts 
of gonorrhoea, women with anorectal 
symptoms, women who had been sexually 
assaulted). 
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van Liere et al., 2014 16 52 (8·0) 21 (3·2) 3 (0·5) 578 (88·4) 654 16 (2·4) 187 (28·6) 39 (6·0) 412 (63·0) 654  
van Rooijen et al., 201528      154 (9.3) 1502 (90.7) n/a n/a 1656 All women reported a history of AI. 
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DISCUSSION:  
This systematic review and meta-analysis of 14 studies found a summary estimate of rectal CT 
positivity of 6·0% among routine-clinic attending women in high-income countries. However, 
because of high heterogeneity and bias due to the populations sampled, this is a likely overestimate 
of population prevalence of rectal CT in women. We calculated that 68·1% of routine clinic-attending 
women infected with urogenital CT also had rectal CT, which is important for treatment implications, 
as azithromycin is a recommended first line treatment for urogenital CT but is less effective for rectal 
CT.  2·2% of routine clinic-attending women without urogenital CT had a rectal CT infection which 
would go undetected if they only have urogenital testing. Most interestingly, this analysis did not 
find a relationship between rectal CT and reported AI, and therefore we believe that currently there 
is insufficient evidence to guide practice on using reported AI as an indicator for rectal testing, as 
recommend by WHO guidelines15. 
A key strength of our study is that we employed a robust methodology to search for and review 
papers following an a priori protocol with clear inclusion and exclusion criteria. We searched several 
databases, assessed papers for risk-of-bias, and undertook double extraction. Our findings are 
subject to limitations, arising from the nature of included studies. Firstly, estimates cannot be 
applied to the general population as all 14 studies included women attending sexual health services, 
limiting the generalisability. Secondly, sexual health clinic populations varied thus limiting 
comparability. Thirdly, there was no consistent definition of history of AI so findings should be 
interpreted with caution. Similarly, ‘high-risk’ women were inconsistently defined.  
This is the first systematic review of the prevalence of rectal CT in heterosexual women in high-
income countries. A non-systematic review of the literature on extragenital infections showed 
similar findings for rectal CT positivity and also highlighted that extragenital infections are often 
found in the absence of reported risk behaviours such as AI6. However, the authors did not calculate 
an estimate for concurrent urogenital CT or RR for AI and rectal CT.  
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 The uncertainty regarding rectal CT infections representing true infections versus contamination 
could not be taken into account in this review given that included studies did not undertake any 
testing method to rule out contamination.  
Although questions remain about the meaning of a rectal CT diagnosis, our study raises some 
important issues concerning CT testing and treatment policies. We found that a summary estimate 
of 68·1% of routine clinic-attending women with urogenital CT had concurrent rectal CT. While the 
relative efficacy of azithromycin versus doxycycline for rectal CT in women has not been definitively 
established, a high proportion of routine-clinic-attending women may be subject to less-effective 
treatment, if given azithromycin directed at their urogenital infection in the absence of rectal 
testing. Assuming our estimate to be true and combining it with a previous estimate of azithromycin 
effectiveness for rectal CT of 82·9% (95% CI 76·0%-89·8%)14 suggests that among routine clinic 
attending women diagnosed with urogenital CT, only approximately half (56%; calculated by 68.1% 
multiplied by 82.9%) would receive adequate treatment if their rectal infection remained 
undiagnosed and they had received azithromycin. Furthermore in approximately 12% (calculated by 
17.1% multiplied by 68.1%) treatment would have failed. In genitourinary medicine clinics in England 
2015, there were 794,168 CT tests and 50,708 diagnoses reported among women (all ages)35. 
Applying our results to this surveillance data shows the potential scale of less-effective treatment 
(diagnoses multiplied by 56%) in women attending sexual health services. If we assume all tests and 
diagnoses were for urogenital CT only, and that azithromycin is prescribed, in this scenario, 
approximately 28,400 CT infections may have been less-effectively treated and approximately 6,000 
infections would fail to be treated (diagnoses multiplied by 12%). However, in practice, some 
clinicians are likely to further assess the need for rectal CT testing (e.g. through history of AI) and 
manage accordingly so fewer infections are likely to be at risk of less-effective treatment.  
Furthermore, our finding that an estimate of 2·2% of routine clinic-attending women without a 
urogenital CT infection had rectal CT suggests a number of rectal CT infections could be missed even 
among those actively engaged in testing. Among all studies with available data, only 13·5% of rectal 
CT detected were among women reporting AI. Therefore, limiting testing and treating for rectal CT 
to women reporting a history of AI or rectal symptoms (as recommended by current guidelines) 
Page 16 of 20 
 
could miss a significant number of rectal infections which has potential implications for current CT 
control programmes.   
These findings suggest that less-effective treatment and missed diagnoses in women may be 
occurring on a considerable scale. However the clinical significance of missed and untreated rectal 
CT in women is still uncertain. Furthermore, the potential impact of less-effective treatment may not 
be as great because in practice, some women receive doxycycline as first line treatment for 
urogenital CT; currently this proportion is unknown. 
From our findings it is clear that current evidence is insufficient to make a robust recommendation 
regarding routine rectal CT testing in women across settings and the use of history of AI as a reliable 
indicator, highlighting the need for further research. While the evidence is limited, rectal testing 
could be done in women who repeatedly present with a urogenital infection within 3 to 6 months of 
treatment. Current BASHH guidance in the UK on the management of CT infection states that those 
who test positive should be retested after 3 months to identify reinfection2. Positive tests at this 
stage could be tested for rectal infection or simply treated for rectal infection. High rates of 
concurrent rectal and urogenital CT is not enough to warrant the use of doxycycline rather than 
azithromycin for first line treatment of women with urogenital CT, however a randomised controlled 
trial of azithromycin versus doxycycline in women for the treatment of rectal CT would determine 
whether individuals with a diagnosed urogenital CT infection but undiagnosed rectal CT who are 
treated with azithromycin are being treated sub-optimally. Data on current prescribing 
(azithromycin or doxycycline for urogenital CT) and extragenital testing practices in specialist and 
non-specialist settings would add understanding to the scale of potential less-effective treatment. 
High-income countries with national testing and treatment policies also require a robust estimate of 
rectal CT among their target populations. Biological studies on bacterial viability as well as non-
urogenital sources of rectal CT infection such as orally acquired12,36 would further allow implications 
of rectal CT to be better understood. Studies to ascertain feasibility, costs and acceptability of 
different testing strategies, are also needed to understand how rectal testing may best be 
incorporated into clinical pathways. It would be interesting to determine if other clinical practices 
such as who obtains the sample, specimen type, the invasiveness of the swab, affects the positivity 
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rate of rectal chlamydia.  Finally, there is a need for studies to determine the significance of rectal CT 
in women by understanding the natural history and complications associated with rectal CT.  
In conclusion, we have found evidence that a substantial proportion of women attending sexual 
health clinics are infected with rectal CT and that the infections risk being missed or less-effectively 
treated. Further work is needed to determine the feasibility of and criteria for routine rectal testing 
in women. 
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